PE20211420A1 - COMPOSICIONES DE AGENTE DE ARNi DE PROTEINA PRECURSORA DE AMILOIDE (APP) Y METODO DE USO DE LAS MISMAS - Google Patents
COMPOSICIONES DE AGENTE DE ARNi DE PROTEINA PRECURSORA DE AMILOIDE (APP) Y METODO DE USO DE LAS MISMASInfo
- Publication number
- PE20211420A1 PE20211420A1 PE2021000927A PE2021000927A PE20211420A1 PE 20211420 A1 PE20211420 A1 PE 20211420A1 PE 2021000927 A PE2021000927 A PE 2021000927A PE 2021000927 A PE2021000927 A PE 2021000927A PE 20211420 A1 PE20211420 A1 PE 20211420A1
- Authority
- PE
- Peru
- Prior art keywords
- compositions
- app
- same
- rnai agent
- precursor protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a agentes y composiciones de acido ribonucleico de doble cadena (ARNids) que se dirigen al gen de APP, asi como a metodos para inhibir la expresion de un gen de APP y metodos para tratar sujetos que tienen una enfermedad o trastorno asociado a APP, tal como angiopatia amiloide cerebral (CAA) y enfermedad de Alzheimer familiar de inicio temprano (EOFAD o eFAD), usando tales agentes y composiciones de ARNids
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862781774P | 2018-12-19 | 2018-12-19 | |
US201962862472P | 2019-06-17 | 2019-06-17 | |
US201962928795P | 2019-10-31 | 2019-10-31 | |
PCT/US2019/067449 WO2020132227A2 (en) | 2018-12-19 | 2019-12-19 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211420A1 true PE20211420A1 (es) | 2021-08-03 |
Family
ID=71101909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000927A PE20211420A1 (es) | 2018-12-19 | 2019-12-19 | COMPOSICIONES DE AGENTE DE ARNi DE PROTEINA PRECURSORA DE AMILOIDE (APP) Y METODO DE USO DE LAS MISMAS |
Country Status (18)
Country | Link |
---|---|
US (2) | US11034957B2 (es) |
EP (1) | EP3898979A4 (es) |
JP (1) | JP2022515193A (es) |
KR (1) | KR20210111780A (es) |
CN (1) | CN113454222A (es) |
AU (1) | AU2019405783A1 (es) |
BR (1) | BR112021011895A2 (es) |
CA (1) | CA3124090A1 (es) |
CL (1) | CL2021001605A1 (es) |
CO (1) | CO2021009163A2 (es) |
CR (1) | CR20210393A (es) |
DO (1) | DOP2021000126A (es) |
IL (1) | IL283852A (es) |
MX (1) | MX2021007570A (es) |
PE (1) | PE20211420A1 (es) |
SG (1) | SG11202105886QA (es) |
TW (1) | TW202039844A (es) |
WO (1) | WO2020132227A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10357588B2 (en) | 2012-05-29 | 2019-07-23 | 3M Innovative Properties Company | Absorbent article comprising polymeric foam and intermediates |
US11732260B2 (en) | 2018-03-02 | 2023-08-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-β precursor protein |
KR20230043914A (ko) * | 2020-07-28 | 2023-03-31 | 아이오니스 파마수티컬즈, 인코포레이티드 | App 발현을 감소시키기 위한 화합물 및 방법 |
WO2022165172A1 (en) * | 2021-01-29 | 2022-08-04 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing amyloid precursor protein (app) |
WO2023039503A2 (en) * | 2021-09-10 | 2023-03-16 | Alnylam Pharmaceuticals, Inc. | App irna compositions and methods of use thereof for treating or preventing diseases characterized by enlarged endosomes |
TW202333750A (zh) * | 2021-11-08 | 2023-09-01 | 美商黛瑟納製藥公司 | RNAi寡核苷酸共軛體 |
WO2023173061A2 (en) * | 2022-03-11 | 2023-09-14 | University Of Massachusetts | Oligonucleotides for app modulation |
WO2023207615A1 (zh) * | 2022-04-26 | 2023-11-02 | 南京明德新药研发有限公司 | 一类含由天然核苷酸组成突出端的双链RNAi化合物 |
WO2023224979A1 (en) * | 2022-05-16 | 2023-11-23 | University Of Massachusetts | Optimized sirna scaffolds |
WO2023230465A1 (en) * | 2022-05-23 | 2023-11-30 | Switch Therapeutics Inc. | Antisense oligonucleotides |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080032942A1 (en) * | 2000-08-30 | 2008-02-07 | Mcswiggen James | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
WO2005003350A2 (en) * | 2003-06-27 | 2005-01-13 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER’S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050209179A1 (en) * | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US8101348B2 (en) | 2002-07-10 | 2012-01-24 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | RNA-interference by single-stranded RNA molecules |
US7851615B2 (en) * | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
GB0324854D0 (en) * | 2003-10-24 | 2003-11-26 | Expresson Biosystems Ltd | App/ena antisense |
JP5683261B2 (ja) * | 2008-03-11 | 2015-03-11 | 学校法人 埼玉医科大学 | 癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬 |
EP2510098B1 (en) * | 2009-12-09 | 2015-02-11 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
KR20130100278A (ko) * | 2010-08-31 | 2013-09-10 | 머크 샤프 앤드 돔 코포레이션 | 올리고뉴클레오티드의 전달을 위한 신규 단일 화학 존재물 및 방법 |
US9127274B2 (en) * | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
JP6126088B2 (ja) * | 2012-05-26 | 2017-05-10 | 株式会社ボナック | デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子 |
SI2929031T1 (en) * | 2012-12-05 | 2018-02-28 | Alnylam Pharmaceuticals, Inc. | PCSK9 IRNA assemblies and procedures for their use |
EP3186377A1 (en) * | 2014-08-20 | 2017-07-05 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
JOP20200115A1 (ar) * | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
US10900041B2 (en) * | 2015-10-16 | 2021-01-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in treating Alzheimer's disease |
JP7353301B2 (ja) * | 2018-05-07 | 2023-09-29 | アルニラム ファーマスーティカルズ インコーポレイテッド | 肝臓外送達 |
WO2020160163A1 (en) * | 2019-01-29 | 2020-08-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing app expression |
EP3983077A4 (en) * | 2019-06-17 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM |
-
2019
- 2019-12-19 PE PE2021000927A patent/PE20211420A1/es unknown
- 2019-12-19 BR BR112021011895-0A patent/BR112021011895A2/pt unknown
- 2019-12-19 TW TW108146697A patent/TW202039844A/zh unknown
- 2019-12-19 CA CA3124090A patent/CA3124090A1/en active Pending
- 2019-12-19 CR CR20210393A patent/CR20210393A/es unknown
- 2019-12-19 JP JP2021536024A patent/JP2022515193A/ja active Pending
- 2019-12-19 MX MX2021007570A patent/MX2021007570A/es unknown
- 2019-12-19 SG SG11202105886QA patent/SG11202105886QA/en unknown
- 2019-12-19 WO PCT/US2019/067449 patent/WO2020132227A2/en unknown
- 2019-12-19 KR KR1020217022070A patent/KR20210111780A/ko unknown
- 2019-12-19 AU AU2019405783A patent/AU2019405783A1/en active Pending
- 2019-12-19 EP EP19900781.6A patent/EP3898979A4/en active Pending
- 2019-12-19 CN CN201980092566.2A patent/CN113454222A/zh active Pending
-
2020
- 2020-07-09 US US16/925,286 patent/US11034957B2/en active Active
-
2021
- 2021-05-07 US US17/314,909 patent/US20220002724A1/en active Pending
- 2021-06-09 IL IL283852A patent/IL283852A/en unknown
- 2021-06-17 CL CL2021001605A patent/CL2021001605A1/es unknown
- 2021-06-18 DO DO2021000126A patent/DOP2021000126A/es unknown
- 2021-07-14 CO CONC2021/0009163A patent/CO2021009163A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210111780A (ko) | 2021-09-13 |
JP2022515193A (ja) | 2022-02-17 |
CR20210393A (es) | 2021-10-27 |
EP3898979A2 (en) | 2021-10-27 |
US20200339991A1 (en) | 2020-10-29 |
DOP2021000126A (es) | 2021-09-30 |
IL283852A (en) | 2021-07-29 |
US11034957B2 (en) | 2021-06-15 |
BR112021011895A2 (pt) | 2021-09-08 |
EP3898979A4 (en) | 2022-10-12 |
CL2021001605A1 (es) | 2021-12-24 |
MX2021007570A (es) | 2021-08-24 |
US20220002724A1 (en) | 2022-01-06 |
WO2020132227A3 (en) | 2020-07-30 |
SG11202105886QA (en) | 2021-07-29 |
CA3124090A1 (en) | 2020-06-25 |
TW202039844A (zh) | 2020-11-01 |
CN113454222A (zh) | 2021-09-28 |
AU2019405783A1 (en) | 2021-07-01 |
WO2020132227A2 (en) | 2020-06-25 |
CO2021009163A2 (es) | 2021-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211420A1 (es) | COMPOSICIONES DE AGENTE DE ARNi DE PROTEINA PRECURSORA DE AMILOIDE (APP) Y METODO DE USO DE LAS MISMAS | |
CL2020002019A1 (es) | Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582) | |
CL2018001404A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos. | |
WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
BR112017023161A2 (pt) | composições de ácido obeticólico e métodos de uso | |
BR112019006106A2 (pt) | formulação carregada com canabinoide, processo para preparar a formulação carregada com canabinoide, composições farmacêutica e nutracêutica, e, método de tratamento de um indivíduo sofrendo de uma enfermidade ou um distúrbio. | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
CU20190045A7 (es) | Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas que son inhibidores de la dihidroorotato deshidrogenasa (dhodh) útiles para el tratamiento o prevención de trastornos hiperproliferativos e inflamatorios | |
CO2017004715A2 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos | |
PE20181131A1 (es) | COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS | |
CL2020002401A1 (es) | Composiciones de arni de 17 b-hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas. | |
EA201890571A1 (ru) | Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9) | |
BR112014011896A2 (pt) | agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr) | |
WO2014022739A3 (en) | Modified rnai agents | |
PH12019550076A1 (en) | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
UY34701A (es) | Formas sólidas de un profármaco de nucleótidos de tiofosforamidato | |
BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
PE20160030A1 (es) | COMPOSICIONES DE ARNi DE SERPINA 1 Y SUS METODOS DE USO | |
BR112018010564A2 (pt) | composições farmacêuticas compreendendo levodopa amida e usos das mesmas | |
AR102777A1 (es) | COMPOSICIONES DE ARNi CONTRA TMPRSS6 Y MÉTODOS PARA SU USO | |
MX2018004043A (es) | Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados. | |
DOP2016000102A (es) | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112016027674A2 (pt) | Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas | |
BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos |